PT  - JOURNAL ARTICLE
AU  - A. Omame
AU  - N. Sene
AU  - I. Nometa
AU  - C. I. Nwakanma
AU  - E. U. Nwafor
AU  - N. O. Iheonu
AU  - D. Okuonghae
TI  - Analysis of COVID-19 and comorbidity co-infection Model with Optimal Control
AID  - 10.1101/2020.08.04.20168013
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.04.20168013
4099  - http://medrxiv.org/content/early/2020/09/10/2020.08.04.20168013.short
4100  - http://medrxiv.org/content/early/2020/09/10/2020.08.04.20168013.full
AB  - The new coronavirus disease 2019 (COVID-19) infection is a double challenge for people infected with comorbidities such as cardiovascular and cerebrovascular diseases and diabetes. Comorbidities have been reported to be risk factors for the complications of COVID-19. In this work, we develop and analyze a mathematical model for the dynamics of COVID-19 infection in order to assess the impacts of prior comorbidity on COVID-19 complications and COVID-19 re-infection. The model is simulated using data relevant to the dynamics of the diseases in Lagos, Nigeria, making predictions for the attainment of peak periods in the presence or absence of comorbidity. The model is shown to undergo the phenomenon of backward bifurcation caused by the parameter accounting for increased susceptibility to COVID-19 infection by comorbid susceptibles as well as the rate of re-infection by those who have recovered from a previous COVID-19 infection. Sensivity analysis of the model when the population of individuals co-infected with COVID-19 and comorbidity is used as response function revealed that the top ranked parameters that drive the dynamics of the co-infection model are the effective contact rate for COVID-19 transmission, βCV, the parameter accounting for increased sucseptibility to COVID-19 by comorbid susceptibles, χCM, the comorbidity development rate, θCM, the detection rate for singly infected and co-infected individuals, η1 and η2, as well as the recovery rate from COVID-19 for co-infected individuals, φI2. Simulations of the model reveal that the cumulative confirmed cases (without comorbidity) may get up to 180,000 after 200 days, if the hyper susceptibility rate of comorbid susceptibles is as high as 1.2 per day. Also, the cumulative confirmed cases (including those co-infected with comorbidity) may be as high as 1000,000 cases by the end of November, 2020 if the re-infection rates for COVID-19 is 0.1 per day. It may be worse than this if the re-infection rates increase higher. Moreover, if policies are strictly put in place to step down the probability of COVID-19 infection by comorbid susceptibles to as low as 0.4 per day and step up the detection rate for singly infected individuals to 0.7 per day, then the reproduction number can be brought very low below one, and COVID-19 infection eliminated from the population. In addition, optimal control and cost-effectiveness analysis of the model reveal that the the strategy that prevents COVID-19 infection by comorbid susceptibles has the least ICER and is the most cost-effective of all the control strategies for the prevention of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding for the researchAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Federal University of Technology Owerri, NigeriaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on https://covid19.ncdc.gov.ng https://covid19.ncdc.gov.ng